References
- Efavirenz. Full Prescribing Information, Dosage & Side Effects. Available at www.mims.com/USA/drug/info/efavirenz/. Accessed 12 February 2012
- Adkins JC, Noble S. Efavirenz. Drugs. 1998;56(6):1055-64; 1065-6. This article on PubMed
- Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy. 2002; 22:930-933. This article on PubMed
- Bahal SM, Romansky JM, Alvarez FJ. Medium chain triglycerides as vehicle for palatable oral liquids. Pharm Dev Technol. 2003;8(1):111-5. This article on PubMed
- Sathigari S, Chadha G, Lee YH, Wright N, et al. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS PharmSciTech. 2009;10(1):81-7. This article on PubMed
- Curi AL, Freeman G, Kapembwa M, Pavesio C. Retinal toxicity due to Efavirenz. Eye (Lond). 2001 Apr;15(Pt 2):246-8. This article on PubMed
- Pasticci MB, Bonora S, DI Candilo F, Lapalorcia LM, Palladino N, Baldelli F. Transitory severe CNS adverse effects after accidental efavirenz overdose during post-exposure HIV prophylaxis. J Chemother. 2007;19(1):110. This article on PubMed
- Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001; 15:71-75. This article on PubMed
- Boscacci, Rémy Ta; Buclin, Thierryb; Furrer, Hansjakoba; et al. A case of voluntary intoxication with efavirenz and lamivudine. AIDS. 2006 ;20 (9): 1352-1354. This article on PubMed
- Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229-37. This article on PubMed